PMID: 9548414Apr 21, 1998Paper

Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro

European Journal of Haematology
P TosiS Tura

Abstract

Karyotype represents the major independent prognostic factor for response and remission duration in acute leukemia. In particular, it has been reported that acute myeloid leukemia (AML) patients with inv(16) abnormality show a better prognosis, especially in case of treatment with high-dose Ara-C (HD Ara-C) containing regimens. In this study we aimed at testing whether leukemic cells from patients showing the inv(16) were more sensitive to Ara-C in vitro, compared to AML blasts from patients with normal karyotype or chromosomal abnormalities other than t(15;17) or t(8;21). We analyzed blast cells from 30 patients who were diagnosed and treated in our institution. The IC50 of Ara-C, as tested by the XTT colorimetric assay, was significantly lower in cases with inv(16) (18.5+/-15.88 micromol/l vs. 38+/-14.6 micromol/l,in cases with other abnormalities, p=0.01). This result was confirmed by a higher incorporation of [3H]-Ara-C into DNA (p=0.02 and p=0.001 compared to samples with normal and abnormal karyotype, respectively). All the same, Ara-C induced apoptosis was significantly increased in cells from patients with inv(16). Our data suggest a possible interaction between the molecular background of inv(16) and a modification of ...Continue Reading

References

Jul 1, 1985·The Journal of Clinical Investigation·H M KantarjianE J Freireich

❮ Previous
Next ❯

Citations

Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Apr 2, 2005·British Journal of Haematology·Charles CraddockDavid Grimwade
Feb 19, 2002·Expert Opinion on Biological Therapy·Øystein BruserudStein Ove Døskeland
Oct 20, 2004·British Journal of Haematology·C M Zwaan, G J L Kaspers
Oct 26, 1999·European Journal of Haematology·J M NørgaardP Hokland
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
Jul 6, 2000·Current Opinion in Hematology·E Berman
Apr 20, 2004·Critical Reviews in Oncology/hematology·Jan Maxwell NørgaardPeter Hokland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis